Welcome to the Current Issues section of the International Journal of Innovations in Oncology Pharmacy Practice (IJIOPP). This space offers seamless access to all published volumes and issues, ensuring that readers, researchers, and professionals can stay up to date with the latest developments and breakthroughs in oncology pharmacy practice.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Pharmacokinetic Evaluation of Novel Liposomal Irinotecan Formulations in Metastatic Colorectal Cancer
Vol.2(1); Pages:1-9. Published on April-2026
Abstract
This study investigates the pharmacokinetic profile and therapeutic efficacy of a novel liposomal formulation of irinotecan in patients diagnosed with metastatic colorectal cancer. A randomized controlled design was employed, enrolling 180 patients across three tertiary oncology centers. Participants were allocated into two groups receiving either conventional irinotecan or the liposomal formulation. Plasma drug concentrations, half-life, and bioavailability were assessed alongside tumor response rates and adverse drug reactions. Results demonstrated a statistically significant increase in systemic circulation time and improved tumor targeting in the liposomal group. Additionally, reduced gastrointestinal toxicity and neutropenia incidence were observed. Pharmacokinetic modeling indicated enhanced drug stability and controlled release properties, supporting improved clinical outcomes. These findings highlight the potential of liposomal irinotecan as a superior alternative in chemotherapy regimens. The study underscores the importance of formulation innovation in oncology pharmacy practice and provides a basis for further large-scale trials and regulatory consideration.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Impact of Pharmacist-Led Medication Reconciliation on Chemotherapy Safety Outcomes
Vol.2(1); Pages:10-19. Published on April-2026
Abstract
Medication errors remain a critical concern in oncology settings due to the complexity of chemotherapy regimens. This prospective cohort study evaluates the effectiveness of pharmacist-led medication reconciliation in reducing discrepancies and improving patient safety. Conducted over six months, the study included 250 oncology patients undergoing chemotherapy. Clinical pharmacists performed systematic reconciliation at admission and prior to each treatment cycle. The intervention group showed a 45% reduction in medication discrepancies compared to standard care. Furthermore, adverse drug events were significantly minimized, particularly those related to dosing errors and drug interactions. Patient adherence and satisfaction scores also improved, reflecting enhanced understanding of treatment protocols. The study demonstrates that integrating pharmacists into multidisciplinary oncology teams significantly contributes to safer chemotherapy practices. These findings support policy-level recommendations for structured medication reconciliation programs in oncology departments globally.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Evaluation of Immune Checkpoint Inhibitor Toxicity Management Protocols in Hospital Pharmacies
Vol.2(1); Pages:20-28. Published on April-2026
Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment paradigms but are associated with unique immune-related adverse events (irAEs). This retrospective observational study examines the effectiveness of toxicity management protocols implemented in hospital pharmacy settings. Data from 320 patients receiving ICIs over one year were analyzed, focusing on incidence, management strategies, and patient outcomes. Findings revealed that standardized pharmacist-driven protocols significantly improved early detection and management of irAEs, reducing hospitalization rates and treatment discontinuation. Corticosteroid stewardship and patient education were key components contributing to improved outcomes. Variability in protocol adherence highlighted the need for consistent training and guideline reinforcement. The study emphasizes the critical role of oncology pharmacists in optimizing immunotherapy safety and supports the development of unified toxicity management frameworks across healthcare institutions.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stability Analysis of Compounded Oral Anticancer Suspensions in Pediatric Oncology
Vol.2(1); Pages:29-39. Published on May-2026
Abstract
Pediatric oncology often necessitates extemporaneous compounding of oral anticancer formulations due to the lack of commercially available age-appropriate dosage forms. This experimental laboratory study evaluates the physicochemical stability and microbial integrity of compounded oral suspensions of commonly used anticancer drugs. Samples were prepared under standardized aseptic conditions and stored under varying temperature and light conditions. Analytical assessments, including high-performance liquid chromatography and microbial testing, were conducted over a 30-day period. Results indicated that certain formulations maintained stability for up to 21 days under refrigeration, while others demonstrated rapid degradation at room temperature. The presence of specific excipients influenced both stability and palatability. These findings provide critical insights for hospital pharmacists in optimizing compounding practices and ensuring safe pediatric dosing. The study advocates for standardized stability guidelines and improved formulation strategies in pediatric oncology pharmacy.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Digital Integration of Oncology Pharmacy Services: Effects on Workflow Efficiency and Patient Outcomes
Vol.2(1); Pages:40-49. Published on June-2026
Abstract
The integration of digital technologies in oncology pharmacy practice has the potential to enhance workflow efficiency and patient care outcomes. This mixed-methods study evaluates the implementation of electronic prescribing systems, automated dispensing units, and clinical decision support tools across three major oncology centers. Quantitative data on prescription errors, dispensing time, and patient throughput were analyzed alongside qualitative interviews with pharmacists and clinicians. Results demonstrated a 35% reduction in medication errors and a significant improvement in workflow efficiency following digital integration. Participants reported enhanced communication, reduced cognitive burden, and improved patient counseling capabilities. However, challenges such as system interoperability and training requirements were identified. The study concludes that digital transformation in oncology pharmacy practice offers substantial benefits but requires strategic planning and continuous evaluation. These findings contribute to the growing body of evidence supporting technology-driven healthcare innovation.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
